MindMaze Therapeutics Holding S.A.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a RLFTF research report →
Price Chart
About the company
MindMaze Therapeutics Holding SA engages in the development of AI-powered neurotherapeutics and pharmacological treatments for brain disorders. It focuses on addressing neurological and neuropsychiatric conditions through advanced research, clinical development, and technology-driven solutions. The company is headquartered in Geneva, Switzerland.
- CEO
- Zach Henderson
- IPO
- 2021
- Employees
- 10
- HQ
- Geneva, GE, CH
Get TickerSpark's AI analysis on RLFTF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
Latest fiscal year · YoY change
- Revenue
- $642.31K-92.4%
- Gross Profit
- $-1,047,501-117.9%
- Op Income
- $-10,520,040
- Net Income
- $-9,910,748+42.1%
- EPS
- $-0.48+65.0%
- OCF Growth
- -136.6%
- FCF Growth
- -325.5%
- 52W High
- $4.88
- 52W Low
- $0.16
- 50D MA
- $0.28
- 200D MA
- $1.24
- Beta
- 1.23
- RSI (14)
- 47
- Avg Volume
- 4.23K
No earnings-call transcripts are available for RLFTF yet.
- Free Float
- 76.3%
- Shares Outstanding
- 12.59M
- Float Shares
- 9.61M
Our RLFTF coverage
Recent articles, reports, and earnings notes.
No research on RLFTF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate RLFTF report →Relief Therapeutics Shareholders Approve Business Combination with NeuroX
accessnewswire.com · Nov 14
Relief Therapeutics Announces Positive Results from Pivotal Bioequivalence Study of RLF-OD032
accessnewswire.com · Oct 29
Relief Therapeutics Publishes 2025 Half-Year Report
accessnewswire.com · Aug 14
Relief Therapeutics Advances Publication of 2025 Half-Year Report
accessnewswire.com · Aug 11
Relief Therapeutics Announces Proposed Business Combination with NeuroX, Successor to MindMaze
accessnewswire.com · Jul 29
Relief Therapeutics Receives FDA Response to QIDP Request for RLF-TD011
accessnewswire.com · Jun 20
Relief Therapeutics Announces Results of Annual General Meeting
accessnewswire.com · Jun 12
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.